← Leaderboards
Janet A Englund
Seattle Children'S Hospital
$13,338,199
Attributed
$25,446,609
Total exposure
4
Grants
3
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $5.9M · FY2011–25$10M$7.5M$5M$2.5M$0
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
CDC$21,317,954 · 3
NIH$4,128,655 · 1
By mechanism
U01$21,317,954 · 3
R01$4,128,655 · 1
Top collaborators
- Eileen Klein14 shared
- Betsy C. Herold6 shared
- William J Steinbach6 shared
- Gabriela Maria Maron4 shared
- Elaine Tuomanen2 shared
Most similar at Seattle Children'S Hospital
Same institution · by research overlap
- Stephanie Duggins Davis$6,278,112
- Alpana Amalkant Waghmare$3,815,503
- Angela Jean Peck Campbell$681,922
- Christopher Hooper Goss$12,695,799
- Pradeep Singh$15,010,155
Others in their field
Top investigators on “Disease Progression”
- Lawrence Corey · Fred Hutchinson Cancer Center$405,086,239
- Constance Ann Benson · University Of California, San Diego$244,117,339
- Jeffrey P Krischer · University Of South Florida$225,151,653
- Douglas S. Hawkins · Children'S Hosp Of Philadelphia$157,315,120
- Glenda E Gray · Wits Health Consortium (Pty), Ltd$150,116,206
- Peter B. Gilbert · Fred Hutchinson Cancer Center$146,027,526
Research focus
Disease ProgressionDisorder RiskDiagnosisDisease OutcomeAge GroupDiagnosticAdaptive Immune ResponseBiological MarkersAntibody ResponseDiagnostic ProcedureBlood SpecimenBronchiolitisCase ControlChildChildhoodBiobankCommon ColdCommunicable DiseasesCoronavirusCovid-19Blood2019-NcovDetectionEarly Intervention
Grant awards (31)
IP21-002, Enhanced Surveillance to Assess Vaccine Preventable Enteric and Respiratory Virus Illnesses$2,082,196
U01 · FY2025 · IP · contact PI
Multi-center Evaluation of the Threat of Established and Emerging Respiratory Viral Infections in Pediatric Transplant Recipients$1,502,393
R01 · FY2025 · AI
IP21-002, Enhanced Surveillance to Assess Vaccine Preventable Enteric and Respiratory Virus Illnesses$1,234,285
U01 · FY2024 · IP · contact PI
Multi-center Evaluation of the Threat of Established and Emerging Respiratory Viral Infections in Pediatric Transplant Recipients$1
R01 · FY2024 · AI
IP21-002, Enhanced Surveillance to Assess Vaccine Preventable Enteric and Respiratory Virus Illnesses$2,749,994
U01 · FY2023 · IP · contact PI
IP21-002, Enhanced Surveillance to Assess Vaccine Preventable Enteric and Respiratory Virus Illnesses$2,300,000
U01 · FY2023 · IP · contact PI
Multi-center Evaluation of the Threat of Established and Emerging Respiratory Viral Infections in Pediatric Transplant Recipients$842,739
R01 · FY2023 · AI
IP21-002, Enhanced Surveillance to Assess Vaccine Preventable Enteric and Respiratory Virus Illnesses$1,933,284
U01 · FY2022 · IP · contact PI
Multi-center Evaluation of the Threat of Established and Emerging Respiratory Viral Infections in Pediatric Transplant Recipients$845,245
R01 · FY2022 · AI
IP21-002, Enhanced Surveillance to Assess Vaccine Preventable Enteric and Respiratory Virus Illnesses$1,441,645
U01 · FY2021 · IP · contact PI
Multi-center Evaluation of the Threat of Established and Emerging Respiratory Viral Infections in Pediatric Transplant Recipients$675,979
R01 · FY2021 · AI
Multi-center evaluation of the threat of established and emerging respiratory viral infections in pediatric transplant recipients$262,298
R01 · FY2021 · AI
Enhanced Surveillance for New Vaccine Preventable Diseases$1,505,484
U01 · FY2020 · IP · contact PI
Enhanced Surveillance for New Vaccine Preventable Diseases$1,000,000
U01 · FY2019 · IP · contact PI
Enhanced Surveillance for New Vaccine Preventable Diseases$300,000
U01 · FY2019 · IP · contact PI
Enhanced Surveillance for New Vaccine Preventable Diseases$1,226,950
U01 · FY2018 · IP · contact PI
Enhanced Surveillance for New Vaccine Preventable Diseases$250,000
U01 · FY2018 · IP · contact PI
Enhanced Surveillance for New Vaccine Preventable Diseases$1,000,000
U01 · FY2017 · IP · contact PI
Enhanced Surveillance for New Vaccine Preventable Diseases$785,715
U01 · FY2016 · IP · contact PI
Enhanced Surveillance for New Vaccine Preventable Diseases$214,285
U01 · FY2016 · IP · contact PI
Enhanced Surveillance for New Vaccine Preventable Disease$499,998
U01 · FY2015 · IP · contact PI
Enhanced Surveillance for New Vaccine Preventable Disease$385,714
U01 · FY2015 · IP · contact PI
Enhanced Surveillance for New Vaccine Preventable Disease$214,285
U01 · FY2015 · IP · contact PI
Enhanced Surveillance for New Vaccine Preventable Disease$391,529
U01 · FY2014 · IP · contact PI
Enhanced Surveillance for New Vaccine Preventable Disease$191,291
U01 · FY2014 · IP · contact PI
Enhanced Surveillance for New Vaccine Preventable Disease$391,529
U01 · FY2013 · IP · contact PI
Enhanced Surveillance for New Vaccine Preventable Disease$158,471
U01 · FY2013 · IP · contact PI
Enhanced Surveillance for New Vaccine Preventable Disease$296,947
U01 · FY2012 · IP · contact PI
Enhanced Surveillance for New Vaccine Preventable Disease$215,030
U01 · FY2012 · IP · contact PI
Enhanced Surveillance for New Vaccine Preventable Disease$348,102
U01 · FY2011 · IP · contact PI
Enhanced Surveillance for New Vaccine Preventable Disease-Patient Protection-ACA$201,220
U01 · FY2011 · IP · contact PI